November 18, 2026
Doctor at laptop
IMS 2026 Multiple Myeloma

Five-year remission rates with cilta-cel in earlier-line relapsed or refractory multiple myeloma

Half of patients with earlier-line relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) in the CARTITUDE-2 trial achieved remissions lasting five years or more, according to a presentation at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026) in Glasgow, Scotland.

The analysis, led by Adam D. Cohen, MD, of University of Pennsylvania in Philadelphia, reviewed 20 patients from Cohort A of the CARTITUDE-2 trial that rolled over to the 15-year follow-up study, CARTinue. This cohort was refractory to lenalidomide with one to three prior lines of therapy, similar to the population in the pivotal CARTITUDE-4 trial.

After a median follow-up of 60.7 months, 10 out of 20 patients remained alive and progression-free. The median progression-free survival was 60.5 months (95% CI, 12.9-not evaluable) and the median overall survival (OS) was not reached. The five-year OS rate was 69.2%. Three patients underwent measurable residual disease testing at five years, and all were negative.

Compared with patients with progressive disease or progressive disease-related death, patients alive and progression-free at five years showed a trend toward lower baseline tumor burden, higher rates of 30% or lower bone marrow plasma cells, higher levels of CD4–positive–naive T-cells at apheresis, and higher CAR–positive, CD4–positive central memory T-cell levels at peak expansion. Of the 10 patients disease-free at five years, five had one or more high-risk cytogenetic features, including four with two or more high-risk features.

“These results build on the long-term outcomes from CARTITUDE-1 and suggest that earlier use of cilta-cel may be associated with a higher likelihood of achieving five-year remissions,” Dr. Cohen and colleagues wrote.

Reference
Cohen AD, Mateos M, Cohen YC, et al. Long-Term (≥5-Year) Remission and Survival With Ciltacabtagene Autoleucel (Cilta-Cel) in Relapsed/Refractory Multiple Myeloma (RRMM) With 1–3 Prior Lines of Therapy: CARTITUDE-2 Cohort A. Abstract PA-288. Presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society; September 23-26, 2026; Glasgow.

Listen to Dr. Thomas Martin interview 1st US patient treated with cilta-cel. 

Leave feedback about this

  • Quality
  • Price
  • Service

PROS

+
Add Field

CONS

+
Add Field